Full-Time
Full-Stack Software Engineer
Backend Leaning
Collate
11-50 employees
AI-driven documentation automation for life sciences
Compensation Overview
$150k - $350k/yr
San Francisco, CA, USA
In Person
 Software Engineering (2) |
|---|
| , |
- Have experience building across the stack, with deeper strength in backend systems.
- Enjoy taking features from idea → backend architecture → polished UI.
- Care deeply about both technical robustness and the end user experience.
- Are motivated by ambiguity, eager to pick up missing knowledge, and excited to solve novel problems.
- Value speed, pragmatism, and scrappiness but know when to design for robustness.
- Have been an early-stage engineer or startup founder—or aspire to work at that level of ownership.
- Design and scale backend services, APIs, and data pipelines that power Collate’s products.
- Deliver end-to-end, production-ready features in partnership with product, design, and AI engineering.
- Balance iteration speed with technical rigor to ensure systems scale reliably.
- Create internal tools and workflows that accelerate engineering productivity.
- Share responsibility for production systems, including participating in on-call rotation.
Collate provides an AI-powered platform that automates the creation and management of documentation for drug development, medical devices, and diagnostics. It works by generating, organizing, and governing regulatory and quality documents while offering data discovery and governance tools to ensure high-quality data assets. It distinguishes itself by offering an end-to-end, life-sciences–focused solution that covers drug, device, and diagnostic workflows in one platform, reducing manual work and speeding up approvals. Its goal is to shorten development and regulatory timelines so researchers can focus on discovery and bring life-saving innovations to patients faster.
Company Size
11-50
Company Stage
Seed
Total Funding
$30M
Headquarters
San Francisco, California
Founded
2025
Simplify's Take
What believers are saying
- Pfizer's 20% manufacturing throughput gains validate AI documentation automation market demand.[5]
- UCSF ARPA-H funding accelerates open-source drug development, creating IND filing opportunities.[5]
- Moderna's AWS AI integration demonstrates enterprise adoption of automated quality control workflows.[5]
What critics are saying
- Pfizer's proprietary generative AI platform directly competes in manufacturing documentation automation.[5]
- FDA's DARRTS system with AI language models bypasses Collate's regulatory submission tools.[7]
- Open-source models from UCSF and Open Molecular Software Foundation commoditize documentation automation.[5]
What makes Collate unique
- Acquired MantleBio to deepen AI capabilities across entire drug development lifecycle.[1]
- Generative AI automates regulatory submissions, clinical trials, and quality management workflows.[2][3]
- AI Studio and SDK enable custom agents without external infrastructure dependencies.[8]
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Equity
Flexible Work Hours
Professional Development Budget
Company News
Biotech startup Collate, founded by Surbhi Sarna, has secured a $30 million seed fund to automate paperwork in the life sciences industry using AI. The funding round was led by Redpoint, with participation from First Round, Conviction Partners, and YC, valuing Collate at over $100 million. Collate aims to streamline documentation for diagnostic, medical device, and drug development companies, enhancing R&D and reducing time to market. Co-founders Nate Smith and Jigish Patel bring additional expertise.
Y Combinator's Surbhi Sarna has raised $30 million for Collate, a startup aiming to automate the tedious parts of running a life sciences business using AI.